Trimtech Raises £25m in Seed Round Backed by Cambridge Innovation Capital
Deal News | Mar 06, 2025 | UK Tech Funding

Trimtech Therapeutics, a biotech spinout from the University of Cambridge, has secured £25m in a seed funding round. The round was co-led by Cambridge Innovation Capital (CIC) and the Dementia Discovery Fund from SV Health Investors. This investment will aid Trimtech in the development of treatments for neurodegenerative diseases, focusing on targeted protein degradation. CIC, having launched its £100m fund the previous month, is supporting domestic deep tech companies like Trimtech to reduce reliance on overseas funding. Alongside CIC and DDF, major players such as Pfizer Ventures, M Ventures, Eli Lilly and Company, MP Healthcare Venture Management, Cambridge Enterprise Ventures, and Start Codon participated in the round. The funds will further Trimtech’s mission to create significant medical advancements for dementia and other central nervous system disorders.
Sectors
- Biotechnology
- Venture Capital
- Pharmaceuticals
Geography
- United Kingdom – Trimtech Therapeutics is a spinout from the University of Cambridge, and the funding is led by Cambridge Innovation Capital, based in the UK.
- United States – Mentions of companies like Pfizer, Eli Lilly, and the trend of moving operations to the US reflect its relevance.
Industry
- Biotechnology – The article focuses on Trimtech Therapeutics, a university spinout working on biotech innovations for neurodegenerative diseases.
- Venture Capital – The funding round was co-led by Cambridge Innovation Capital, a venture capital firm, highlighting its investment in deep tech startups.
- Pharmaceuticals – Participants such as Pfizer Ventures and Eli Lilly indicate the pharmaceutical industry's involvement in funding biotech innovations.
Financials
- £25m – The total amount raised in Trimtech's seed funding round.
- £100m – The fund launched by Cambridge Innovation Capital for deep tech investments.
Participants
Name | Role | Type | Description |
---|---|---|---|
Trimtech Therapeutics | Target Company | Company | A university spinout biotech company focused on neurodegenerative diseases. |
Cambridge Innovation Capital | Co-lead investor | Company | A venture capital firm investing in deep tech companies, co-leading this funding round. |
SV Health Investors Dementia Discovery Fund | Co-lead investor | Company | Co-leader in the funding round, its fund focuses on dementia-related innovations. |
Nicola Thompson | CEO | Person | CEO of Trimtech Therapeutics. |
Michael Anstey | Partner | Person | Partner at Cambridge Innovation Capital, involved in the funding. |
Laurence Barker | Partner | Person | Partner at SV Health Investors Dementia Discovery Fund, involved in the funding. |
Pfizer Ventures | Investor | Company | Participated in the seed funding round. |
M Ventures | Investor | Company | Participated in the seed funding round. |
Eli Lilly and Company | Investor | Company | Participated in the seed funding round. |
MP Healthcare Venture Management | Investor | Company | Participated in the seed funding round. |
Cambridge Enterprise Ventures | Investor | Company | Participated in the seed funding round. |
Start Codon | Investor | Company | Participated in the seed funding round. |